Halbekath J
Z Arztl Fortbild Qualitatssich. 2000 Aug;94(6):453-60.
The goal of drug treatment of osteoporosis is to prevent fractures. Increase of bone density during therapy is not consistently associated with a clinical benefit. The purpose of this paper is to review the evidence of fracture prevention from published randomized controlled trials. Vitamin D, the bisphosphonate alendronate and the selective estrogen receptor modulator raloxifene have been evaluated in large randomized trials with clinical endpoints.
骨质疏松症药物治疗的目标是预防骨折。治疗期间骨密度的增加与临床获益并非始终相关。本文的目的是回顾已发表的随机对照试验中预防骨折的证据。维生素D、双膦酸盐阿仑膦酸钠和选择性雌激素受体调节剂雷洛昔芬已在具有临床终点的大型随机试验中进行了评估。
